Eli Lilly

Eli Lilly and Company is a global pharmaceutical corporation headquartered in Indianapolis, Indiana, with a history spanning nearly 150 years and a portfolio that includes treatments for diabetes, oncology, immunology, and neuroscience.

The company has emerged as one of the pharmaceutical industry's most prominent investors in artificial intelligence, highlighted by a research and licensing agreement with Insilico Medicine valued at up to $2.75 billion — among the largest deals to date placing a major drugmaker's capital directly behind AI-designed drug candidates. The arrangement reflects a broader industry shift in which AI is moving from an experimental tool to central infrastructure across drug discovery and clinical development.

Lilly's commitment mirrors a wave of similar partnerships forming across the sector as established pharmaceutical companies race to compress the time and cost of bringing new medicines to market. For AI and technology observers, these multi-billion-dollar bets by industry incumbents signal that machine-learning-driven drug research has crossed from speculation into mainstream pharmaceutical strategy.